CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Perampanel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02120365
NCT02120365Phase 2Completed
CompareCT.gov

Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence

Virginia Commonwealth University·interventional·Posted Apr 22, 2014·Updated Aug 18, 2023

In Brief

A Phase 2 clinical trial evaluating Perampanel and Placebo for Alcoholism. Completed, enrolled 22 participants across 4 sites.

Detailed Summary

The purpose of this study is to determine whether perampanel alters the response to alcohol for heavy drinkers. It is hypothesized that perampanel will reduce the rewarding and reinforcing properties of alcohol in the laboratory setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
CollaboratorsUniversity of Connecticut, Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 22, 2014
Enrollment StartJun 1, 2019
Primary CompletionFeb 15, 2022
Study CompletionFeb 16, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.2 years ago

Interventions

Perampaneldrug

Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.

Placebodrug

Placebo given in place of perampanel during the pre-treatment period and lab session days.